Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

ALX ONCOLOGY HOLDINGS INC
Next earnings Aug 10, 2026 · consensus $-0.15 EPS
Last earnings +11.2% on 2026-05-08
Mixed signals in the latest filings.
ALX ONCOLOGY HOLDINGS INC shows $0.00 in FY2022 revenue, and -391.4% ROE.
Sources: SEC EDGAR (CIK 0001810182, latest 10-Q filed 2026-05-08) · EODHD · as of 6/22/2026, 1:54:09 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$83.6M | -$127M | -$170M | -$142M | -$104M |
| Net income | -$83.5M | -$123M | -$161M | -$135M | -$102M |
| Diluted EPS | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-03-19 | Lettmann Jason CHIEF EXECUTIVE OFFICER | Sell | 12.3K @ $2.17 | $26.7K |
| 2026-03-19 | Pinto Shelly SVP, FINANCE AND CAO | Sell | 903.00 @ $2.17 | $1.96K |
| 2026-02-18 | Pinto Shelly SVP, FINANCE AND CAO | Sell | 565.00 @ $2.27 | $1.28K |
| 2026-02-17 | Lettmann Jason CHIEF EXECUTIVE OFFICER | Tax | 2.20K @ $2.27 | $5.00K |
| 2026-02-02 | GOODMAN COREY S Director | Buy | 3.18M @ $1.57 | $5.00M |